|
|
작성일 : 22-06-03 12:56
|
글쓴이 :
Corina Hollingsworth (202.♡.6.149)
 조회 : 3,447
|
BRITISH CANNABIS is the leading private Cannabidol brand in the UK. A total of 310 products that are associated with British Cannabis were recently improved to regulators An analysis of the list released by the Food Standards Agency earlier this month shows.
The preliminary approval was granted to 75 products that were submitted by the Berkshire-based business, and 235 submitted jointly with other businesses. FSA preliminarily approved 3,536 items as new or novel foods according to the table, which was published on March 31
RX Pharmatech Ltd. (Bradford, West Yorkshire), which has ties with U.S. This makes it the second-highest approval total. RX Pharmatech submitted 116 product independently and 157 together with other producers.
According to the Association for the Cannabinoid Industry (ACI), the UK's market for CBD products in consumer form was worth PS690 millions (EUR814.5million; $905.7million) by 2021. ACI reported that CBD sales have more than doubled in UK over the past year, making it the non-EU's second largest consumer market, after the USA.
Companies remaining
In total, 374 companies had products approved by the FSA. Some companies submitted applications separately, others as part of joint applications with other producers. Others filed jointly and independently. There were 70 CBD applications submitted to the FSA.
Although products that were included on the list may be allowed to continue selling, products that failed FSA scrutiny will not be permitted to remain on the market. FSA stresses that the approvals were preliminary and that certain products could be removed at later stages.
Many of these products were promoted to pre-validation status ("awaiting proof"), the second phase of FSA's novel product approval process. Fifty-seven products representing five companies are now in the final stage of the approval process, they await the FSA's final decision regarding full authorization.
You are looking for clarity
FSA's novel foods approval process is designed to clarify a growing gray market, which has seen thousands of cannabidol products appear in retail outlets over recent years. The products must have been in circulation before February 13, 2020 to be eligible for agency consideration. Products introduced after that date would not be eligible for consideration.
BRITISH CANNABIS products were presumably obtained from a consortium established by the ACI. ACI stated this week that it is still analysing FSA and would not release any information regarding the number of products or the numbers submitted for applications. ACI has at least 628 products that were developed by members, including British Cannabis.
Applications of EIHA
RX Pharmatech's products were submitted separately by the European Industrial Hemp Association, which saw 1,992 CBD product preliminarily approved.
EIHA Projects GmbH included 193 companies in its submissions of products. The EIHA saw 1,992 CBD products preliminarily approve, accounting for about 56% These products were part of two EIHA applications that covered isolates (1.157) and full spectrum extracts (835).
A quick look at the top companies
Here's a list of the top five companies that were associated with the complete list of 3,536 products, these are based on how many products they had been approved by FSA according to company websites.
British Cannabis
British Cannabis, an independent vertically integrated producer of cannabis, CBD and other cannabinoid product, was founded in 2015.BRITISH CANNABIS supplies white-label products to other brands and makes its own brand products. BRITISH CANNABIS operates its own laboratory, manufacturing facility and warehouse, the company also has dispatch operations and a farm for cannabis research in Portugal. According to the company, it shipped over 50,000 CBD oils to its largest white label clients in the first half 2021, these clients are unidentified but are known as "two of industry's most well-known brands". British Cannabis announced its intention to invest in a new facility. It will include an ISO-accredited cannabis oil analytics testing lab and a cosmetics line. This could increase its potential capacity by up to three times. It is one of 35 UK testing labs responsible for the "chemist trial" assessment that measures CBD and cannabinoid contents in commercial products.
Associated principals : Thomas Whettem CEO & Founder, David Ralston, Managing director
RX Pharmatech Ltd
RX Pharmatech Ltd. doesn't appear to have a website, and very little public information about it is available Based on other sources, the company was founded in May 2016. RX Pharmatech supplies bulk isolates and distillates made by GVB Biopharma, Las Vegas (Nevada), USA. RX Pharmatech have also been a party the second-highest FSA product list. GVB also claimed in a press statement April 7, 2022, that it is the largest supplier to white label formulas for oral tinctures and vape liquids. GVB stated that it sources raw materials from an American farmers cooperative. GVB's website states that the company has a UK branch in Doncaster (Yorkshire, England). GVB's website indicates that there is a UK office located in Doncaster, Yorkshire. GVB only has one investor, Decathlon Capital Partners. GVB claims operations in Europe (location not identified) and Bogota Colombia. GVB Biopharma partnered with Medicaleaf Ltd. (Cheltenham & Gloucestershire) and Isomist Ltd. GVB Biopharma is said to be in an strategic relationship with Sonder Fulfillment. This division of Golden Triangle Ventures is a Las Vegas-based pennystock operator.
Principals associated with RX Pharmatech Ltd. Dominic James Bartle is the director and Damien Jonathan Bove is the director. GVB Biopharma Phillip Swindells is the CEO and co-founder. Jack Feldman is president & Co-founder. Hugh Kinsman is CFO.
Mile High Labs
Mile High Labs, a supplier of CBD and CBN in Colorado, is located in Broomfield. Mile High reported that in 2019, it raised $100 million through two rounds of funding, including $65 million from MGG Investment Group, New York (2019). Mile High has an extraction plant that uses raw materials from contracted CBD hemp growers in America. According to the company's website, there is also a office in Belfast, Northern Ireland.
Associated principals Jonathan Hilley CEO, Ryan Keeler COO, Jodi Gatica VP Quality, Danny Moses, Investor.
Taylor Mammon Ltd
Taylor Mammon Ltd. is a white-label distributor and manufacturer of CBD. It is based in Welwyn Garden City (Hertfordshire). The company operates under the parent company, Kentucky-based GenCanna. OGGUSA Inc. was also known as GenCanna. In May 2020, GenCanna's majority of assets were sold to MGG Investment Group in New York. In May 2020 the bankruptcy court approved GenCanna’s sale to MGG Investment Group, New York. GenCanna purchased Taylor Mammon's UK-based CBD Capital in the last year.
Associated principals : Taylor Mammon - Alex Taylor, cofounder; James Taylor chief commercial officer; Nathan Wogman cofounder and managing director. GenCanna/OGGUSA Inc. - Andrew Barnett, CEO; Hassan Akhtar, managing director, Europe.
Sativa Wellness Group
Although now called Goodbody Health Inc, it submitted its novel foods applications as Sativa Wellness. The Canada-based company is an OTC trader of around 20 CBD products. They sell oils, capsules and gummies online, and have laboratories to test CBD products in the UK. There are also laboratories in the UK and Poland for testing CBD products.Goodbody/Sativa Wellness headquarters is located in Vancouver (British Columbia), with an office in Beckington, Somerset. In 2020, the most recent year that public financial reports are available, the company reported a loss close to $6.5 million (PS5,000,000). Goodbody shares trade at $0.05 (5c) currently. Goodbody's UK affiliate, PhytoVista Laboratories received a controlled drugs license last month (April 2022).
Associated principals (Goodbody Health Inc.): Geremy Tom, Founder & Executive Chair; Marc Howells CEO; Anne Tew CFO and Corporate Secretary.
|
|
|
